A Systematic Review on the Use of Psychosocial Interventions in Conjunction with Medications for the Treatment of Opioid Addiction

Journal of Addiction Medicine

Volumn 10, Issue 2, 2016, Pages 93-103

  Dugosh, Karen ^a   Abraham, Amanda ^a,b   Seymour, Brittany ^a   McLoyd, Keli ^a   Chalk, Mady ^a   Festinger, David ^a  

^a TREATMENT RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF GEORGIA   (United States)

Author keywords

buprenorphine; counseling; medication assisted treatment; methadone; naltrexone; psychosocial

Indexed keywords

BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; METHADONE; NALTREXONE; NARCOTIC ANALGESIC AGENT; NARCOTIC ANTAGONIST;

ACCEPTANCE AND COMMITMENT THERAPY; ARTICLE; CLINICAL EFFECTIVENESS; COGNITIVE THERAPY; COMMUNITY REINFORCEMENT AND FAMILY TRAINING FOR TREATMENT RETENTION; CONTINGENCY MANAGEMENT; COUNSELING; DRUG RELEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; INTERNET; MAINTENANCE THERAPY; MOTIVATIONAL INTERVIEWING; NARCOTIC DEPENDENCE; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SYSTEMATIC REVIEW; TELECONSULTATION; MULTIMODALITY CANCER THERAPY; OPIOID-RELATED DISORDERS; PROCEDURES;

ANALGESICS, OPIOID; BUPRENORPHINE; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; HUMANS; METHADONE; NALTREXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS;

EID: 84964345522     PISSN: 19320620     EISSN: 19353227     Source Type: Journal    
DOI: 10.1097/ADM.0000000000000193     Document Type: Article

References (50)

1. Amato L, Minozzi S, Davoli M, et al. Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification. Cochrane Database Syst Rev 2008;(4). CD005031.
2. Amato L, Minozzi S, Davoli M, et al. Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification. Cochrane Database Syst Rev 2011;(9). CD005031.
3. Amato L, Minozzi S, Davoli M, et al. Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database Syst Rev 2011;(10). CD004147.
4. American Society of Addiction Medicine. Advancing Access to Addiction Medicine: Implications for Opioid Addiction Treatment. American Society of Addiction Medicine; 2013.
5. American Society of Addiction Medicine. The ASAM National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use. American Society of Addiction Medicine; 2015.
6. Brigham GS, Slesnick N, Winhusen TM, et al. A randomized pilot clinical trial to evaluate the efficacy of community reinforcement and family training for treatment retention (CRAFT-T) for improving outcomes for patients completing opioid detoxification. Drug Alcohol Depend 2014;138:240-243.
7. BUNAVAIL [package insert]. Raleigh NC: BioDelivery Sciences International Inc.; Last Revised September; 2014.
8. Carpenter KM, Jiang H, Sullivan MA, et al. Betting on change: modeling transitional probabilities to guide therapy development for opioid dependence. Psychol Addict Behav 2009;23(1):47-55.
9. Carroll KM, Onken LS. Behavioral therapies for drug abuse. Am J Psychiatry 2005;162(8):1452-1460.
10. Center for Behavioral Health Statistics and Quality. Behavioral Health Trends in the United States: Results From the 2014 National Survey on Drug Use and Health (HHS Publication No. SMA 15-4927, NSDUH Series H-50).
11. Center for Behavioral Health Statistics and Quality; 2015, http:// www.samhsa.gov/data/. Accessed October 15, 2015.
12. Centers for Disease Control and Prevention. Vital sign: overdoses of prescription opioid pain relievers-United States, 1999-2008. MMWR Morb Mortal Wkly Rep 2011; 60(43):1487-1492. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6043a4.htm. Accessed October 15, 2015.
13. Centers for Disease Control and Prevention. New HIVinfections in the United States. Centers for Disease Control and Prevention; 2012.
14. Chawarski MC, Zhou W, Schottenfeld RS. Behavioral drug and HIV risk reduction counseling (BDRC) in MMT programs in wuhan, china: A pilot randomized clinical trial. Drug Alcohol Depend 2011;115(3):237-239.
15. Chen W, Hong Y, Zou X, et al. Effectiveness of prize-based contingency management in a methadone maintenance program in china. Drug Alcohol Depend 2013;133(1):270-274.
16. DeFulio A, Everly JJ, Leoutsakos J-MS, et al. Employment-based reinforcement of adherence to an FDA approved extended release formulation of naltrexone in opioid-dependent adults: a randomized controlled trial. Drug Alcohol Depend 2012;120(1-3):48-54.
17. DEPADE [package insert]. Hazelwood MO: Mallinckrodt Inc.; Last Revised November 2014.
18. Drummond DC, Perryman K. Psychosocial Interventions in Pharmacotherapy of Opioid Dependence: A Literature Review. London: St. George's University of London; 2007.
19. Dunn KE, Defulio A, Everly JJ, et al. Employment-based reinforcement of adherence to oral naltrexone treatment in unemployed injection drug users. Exp Clin Psychopharmacol 2013;21(1):74-83.
20. Dutra L, Stathopoulou G, Basden SL, et al. A meta-analytic review of psychosocial interventions for substance use disorders. Am J Psychiatry 2008;165(2):179-187.
21. Everly JJ, DeFulio A, Koffarnus MN, et al. Employment-based reinforcement of adherence to depot naltrexone in unemployed opioid-dependent adults: a randomized controlled trial. Addiction 2011;106(7):1309-1318.
22. Fiellin DA, Barry DT, Sullivan LE, et al. A randomized trial of cognitive behavioral therapy in primary care-based buprenorphine. Am J Med 2013;126(1):74.e11-77.e11.
23. Gerra G, Saenz E, Busse A, et al. Supervised daily consumption, contingent take-home incentive and non-contingent take-home in methadone maintenance. Prog Neuropsychopharmacol Biol Psychiatry 2011;35(2):483-489.
24. Gruber VA, Delucchi KL, Kielstein A, et al. A randomized trial of 6-month methadone maintenance with standard or minimal counseling versus 21- day methadone detoxification. Drug Alcohol Depend 2008;94(1-3):199-206.
25. Gu J, Lau JT, Xu H, et al. A randomized controlled trial to evaluate the relative efficacy of the addition of a psycho-social intervention to standard-of-care services in reducing attrition and improving attendance among first-time users of methadone maintenance treatment in China. AIDS Behav 2013;17(6):2002-2010.
26. Hesse M, Pedersen MU. Easy-access services in low-threshold opiate agonist maintenance. Int J Ment Health Addict 2008;6(3):316-324.
27. Hser YI, Li J, Jiang H, et al. Effects of a randomized contingency management intervention on opiate abstinence and retention in methadone maintenance treatment in China. Addiction 2011;106(10):1801-1809.
28. Jones CM, Logan J, Gladden RW, et al. Vital signs: demographic and substance use trends among heroin users: United states, 2002-2013. MMWR Morb Mortal Wkly Rep 2015;64(26):719-725.
29. Katz EC, Brown BS, Schwartz RP, et al. Transitioning opioid-dependent patients from detoxification to long-term treatment: efficacy of intensive role induction. Drug Alcohol Depend 2011;117:24-30.
30. Kelly SM, Schwartz RP, O'Grady KE, et al. Impact of methadone with versus without drug abuse counseling on HIV risk: 4- and 12-month findings from a clinical trial. J Addict Med 2012;6(2):145-152.
31. Kidorf M, Brooner RK, Gandotra N, et al. Reinforcing integrated psychiatric service attendance in an opioid-agonist program: a randomized and controlled trial. Drug Alcohol Depend 2013;133(1):30-36.
32. Kouimtsidis C, Reynolds M, Coulton S, et al. How does cognitive behaviour therapy work with opioid-dependent clients? Results of the UKCBTMM study. Drugs: Educ Prev Polic 2012;19(3):253-258.
33. Ling W, Hillhouse M, Ang A, et al. Comparison of behavioral treatment conditions in buprenorphine maintenance. Addiction 2013;108(10):1788-1798.
34. Marsch LA, Guarino H, Acosta M, et al. Web-based behavioral treatment for substance use disorders as a partial replacement of standard methadone maintenance treatment. J Subst Abuse Treat 2014;46(1):43-51.
35. Methadone (Dolophine1) DOLOPHINE [package insert]. Columbus OH: Roxane Laboratories Inc.; Revised April 2015.
36. Mitchell SG, Gryczynski J, Schwartz RP, et al. A randomized trial of intensive outpatient (IOP) vs. standard outpatient (op) buprenorphine treatment for African Americans. Drug Alcohol Depend 2013;128(3):222-229.
37. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the prisma statement. Ann Intern Med 2009;151(4):264-269.
38. Moore BA, Barry DT, Sullivan LE, et al. Counseling and directly observed medication for primary care buprenorphine maintenance: a pilot study. J Addict Med 2012;6(3):205-211.
39. Moore BA, Fazzino T, Barry DT, et al. The recovery line: a pilot trial of automated, telephone-based treatment for continued drug use in methadone maintenance. J Subst Abuse Treat 2013;45(1):63-69.
40. National Institute on Drug Abuse. Overdose death rates. 2015. https:// www.drugabuse.gov/related-topics/trends-statistics/overdose-death-rates . Accessed October 15, 2015.
41. Nunes EV, Rothenberg J, Sullivan MA, et al. Behavioral therapy to augment oral naltrexone for opioid dependence: a ceiling on effectiveness. Am J Drug Alcohol Abuse 2006;32:503-517.
42. Nyamathi AM, Nandy K, Greengold B, et al. Effectiveness of intervention on improvement of drug use among methadone maintained adults. J Addict Dis 2011;30(1):6-16.
43. REVIA [package insert]. Pomona NY: Barr Pharmaceuticals Inc.; Revised December 2013.
44. Ruetsch C, Tkacz J, McPherson TL, et al. The effect of telephonic patient support on treatment for opioid dependence: outcomes at one year followup. Addict Behav 2012;37(5):686-689.
45. Stotts AL, Green C, Masuda A, et al. A stage I pilot study of acceptance and commitment therapy for methadone detoxification. Drug Alcohol Depend 2012;125(3):215-222.
46. SUBOXONE [package insert]. Richmond, VA: Reckitt Benckiser Pharmaceuticals Inc.; Last Revised April 2014.
47. SUBUTEX [package insert]. Montgomery, AL: Midlothian Laboratories; Last Revised September 2010.
48. VIVITROL [package insert]. Waltham MA: Alkermes Inc.; Last Revised July 2013.
49. Weiss RD, Potter JS, Fiellin DA, et al. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. Arch Gen Psychiatry 2011;68(12):1238-1246.
50. ZUBSOLV [package insert]. Morristown NJ: Orexo US Inc.; Last Revised December 2014.